Notably, these results clearly indicate that niraparib and olaparib, which have similar in vitro PARP catalytic inhibition potency and cytotoxicity in BRCAmut cells [22] as well as in vivo efficacy in BRCAmut xenograft model, are not equivalent with respect to their effectiveness on tumor growth inhibition, particularly in BRCAwt models. Here, PARP1 is linked to neoplasm.